Colorectal Cancer Screening programme

Colorectal Cancer Screening programme

Health Technology Assessment (HTA) of population-based colorectal cancer screening programme in Ireland

This HTA was prepared by the National Cancer Registry Ireland, the National Centre for Pharmacoeconomics, the School for Health & Related Research, Sheffield University and Dublin City University.  It is available on the HIQA website.

Oncotype DX®

Oncotype DX®

Cost-effectiveness of Oncotype DX® to target chemotherapy use in lymph-node-negative, oestrogen-receptor-positive, early-stage breast cancer in Ireland.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
24/05/2011 22/07/2011 Reimbursement not recommended at the submitted price

3rd October 2011

Following a price revision the NCPE now consider Oncotype DX a cost-effective therapy to target chemotherapy use in lymph-node-negative, oestrogen-receptor-positve, early stage breast cancer in Ireland.

Oncotype DX summary


July 2013

The HSE has approved reimbursement following confidential price negotiations.